The CompBioMed Website Sample Clauses

The CompBioMed Website. At the core of our dissemination activity is the CompBioMed website, where the XxX is described, its partners are detailed, its activities are reported, helpful contact details are listed, and where there is a repository for XxX-related documents generally. The key CompBioMed services are listed prominently on the homepage: The Visitor Programme, the Training Portal, the Software Hub, and Associate Partner Scheme. Also shown prominently are pages filled with content that is tailored to different visitor types: from Academia, Industry, the Clinic, and the General Public. The website can be accessed at the URL xxxx://xxx.xxxxxxxxxx.
AutoNDA by SimpleDocs
The CompBioMed Website. In CompBioMed2, we have of course benefitted hugely from having already developed the project website in CompBioMed1. The website was fine-tuned over the course of the Centre’s first phase and continued into CompBioMed2 as a fully featured hub for the project. We do, of course, continue to update it, not just in terms of news, events, service updates, training etc., but also adding new areas and functionality on the website when needed. For instance, we created the CompBioMed coronavirus portal9, which describes our various threads of work, activity, collaborations, and resources related to coronavirus research. We also added the scalability support portal10, offering free support to improve the scalability of computational biomedicine solutions with high performance computers. More information on the service pages of the website can be found in D4.2, publish at the same time as this deliverable (M25 – October 2021) In terms of website traffic, the CompBioMed website’s 165 pages has seen 139,405 visitors in total, up from 109,908 visitors at the end of CBM1. The website has received 252,687 visits, up from 199,669 visits at the end of CBM1. Trends are difficult to track across the projects since Google’s tracking algorithm changed substantially in September 2018, rendering it impossible to interpret trends that cross that date.
The CompBioMed Website. At the core of our dissemination activity is the CompBioMed website, where the project is described, its partners are detailed, its activities are reported, helpful contact details are listed, and where there is a repository for the project’s training programme and for project-related documents generally. The website can be accessed at the URL xxxx://xxx.xxxxxxxxxx.
The CompBioMed Website. In this section we describe what’s new on the CompBioMed website in the second half of the project. In terms of visitor traffic, the number of visitors and visits coming to the CompBioMed website since the start of the project is shown in Figure 19. Figure 19: Visitor traffic to the CompBioMed website In total there were 109,908 visitors and 199,669 visits to the website’s 129 pages. It should be noted that the large peak in visits during September 2017 does not correlate to a rise in the number of visitors. It is therefore likely due to the action of automated bots and should therefore be ignored. Additionally, there is a notable drop in both visitors and visits around September 7 xxxxx://xxxxxxxxxxxxxxx.xxx/why-computer-simulations-should-replace-animal-testing-for-heart-drugs-93409 2018 and the numbers are lower thereafter. Such a shift is often regarded as the result of a change in the algorithm that was being used to calculate the numbers. The CompBioMed website8 has undergone continual development since month 18 of the project. As described in D3.5, the front page gives prime screen space to buttons that take visitors to content that is tailored to the type of user that they are: Academic, Industry, Clinical, and General Public visitors. The images on the buttons have been upgraded to attractive animations from the Virtual Humans film, which, combined with the scrolling banner image that shows key highlights, gives a dynamic feel to the website’s front page. The General Public page is now designed to take visitors through the core ideas behind Figure 20: The general public page of the CompBioMed website CompBioMed and Computational Biomedicine, harnessing the Virtual Humans film to achieve this. Also, on this page are other videos, a news feed, and a twitter feed. The general public page is shown in Figure 20. To further help the general public and other visitors, the publications page of the website is now formatted into a presentable table that shows short summaries of the research in each paper. The Clinicians page has also been revamped, now showing short summaries of each of CompBioMed’s software applications, along with two descriptive examples of CompBioMed software being used in a way that will interest clinicians. We’ve added a High Performance Computer Allocations page so that partners, associate partners and even external parties can apply to take advantage of computational resources under the control of CompBioMed. The new page provides d...

Related to The CompBioMed Website

  • Web Site Information on registration for and use of the E-Verify program can be obtained via the Internet at the Department of Homeland Security Web site: xxxx://xxx.xxx.xxx/E-Verify.

  • THIRD PARTY WEBSITES AND CONTENT The Website contains (or you may be sent through the Website or the Company Services) links to other websites ("Third Party Websites") as well as articles, photographs, text, graphics, pictures, designs, music, sound, video, information, applications, software and other content or items belonging to or originating from third parties (the "Third Party Content"). Such Third Party Websites and Third Party Content are not investigated, monitored or checked for accuracy, appropriateness, or completeness by us, and we are not responsible for any Third Party Websites accessed through the Website or any Third Party Content posted on, available through or installed from the Website, including the content, accuracy, offensiveness, opinions, reliability, privacy practices or other policies of or contained in the Third Party Websites or the Third Party Content. Inclusion of, linking to or permitting the use or installation of any Third Party Website or any Third Party Content does not imply approval or endorsement thereof by us. If you decide to leave the Website and access the Third Party Websites or to use or install any Third Party Content, you do so at your own risk and you should be aware that our terms and policies no longer govern. You should review the applicable terms and policies, including privacy and data gathering practices, of any website to which you navigate from the Website or relating to any applications you use or install from the Website. Any purchases you make through Third Party Websites will be through other websites and from other companies, and Company takes no responsibility whatsoever in relation to such purchases which are exclusively between you and the applicable third party. SITE MANAGEMENT Company reserves the right but does not have the obligation to:

  • PARTY WEBSITES AND CONTENT The Site may contain (or you may be sent via the Site) links to other websites ("Third- Party Websites") as well as articles, photographs, text, graphics, pictures, designs, music, sound, video, information, applications, software, and other content or items belonging to or originating from third parties ("Third-Party Content"). Such Third-Party Websites and Third-Party Content are not investigated, monitored, or checked for accuracy, appropriateness, or completeness by us, and we are not responsible for any Third-Party Websites accessed through the Site or any Third-Party Content posted on, available through, or installed from the Site, including the content, accuracy, offensiveness, opinions, reliability, privacy practices, or other policies of or contained in the Third-Party Websites or the Third-Party Content. Inclusion of, linking to, or permitting the use or installation of any Third-Party Websites or any Third-Party Content does not imply approval or endorsement thereof by us. If you decide to leave the Site and access the Third-Party Websites or to use or install any Third-Party Content, you do so at your own risk, and you should be aware these Terms and Conditions no longer govern. You should review the applicable terms and policies, including privacy and data gathering practices, of any website to which you navigate from the Site or relating to any applications you use or install from the Site. Any purchases you make through Third- Party Websites will be through other websites and from other companies, and we take no responsibility whatsoever in relation to such purchases which are exclusively between you and the applicable third party. You agree and acknowledge that we do not endorse the products or services offered on Third-Party Websites and you shall hold us harmless from any harm caused by your purchase of such products or services. Additionally, you shall hold us harmless from any losses sustained by you or harm caused to you relating to or resulting in any way from any Third-Party Content or any contact with Third-Party Websites.

  • Information About You and Your Visits to the Website All information we collect on this Website is subject to our Privacy Policy. By using the Website, you consent to all actions taken by us with respect to your information in compliance with the Privacy Policy.

  • Settlement Website Within ten (10) days from entry of the Preliminary Approval Order, Notice shall be provided on a website at an available settlement URL (such as, for example, xxx.XXxxxxxxxxxxxxxxxxxx.xxx) which shall be obtained, administered and maintained by the Settlement Administrator and shall include the ability to file Claim Forms on- line, provided that such Claim Forms, if signed electronically, will be binding for purposes of applicable law and contain a statement to that effect. The Notice provided on the Settlement Website shall be substantially in the form of Exhibit D hereto.

  • RELEASE OF BID EVALUATION MATERIALS Requests concerning the evaluation of Bids may be submitted under the Freedom of Information Law. Information, other than statistical or factual tabulations or data such as the Bid Tabulation, shall only be released as required by law after Contract award. Bid Tabulations are not maintained for all procurements. Names of Bidders may be disclosed after Bid opening upon request. Written requests should be directed to the Commissioner.

  • Public Posting of Approved Users’ Research Use Statement The PI agrees that information about themselves and the approved research use will be posted publicly on the dbGaP website. The information includes the PI’s name and Requester, project name, Research Use Statement, and a Non-Technical Summary of the Research Use Statement. In addition, and if applicable, this information may include the Cloud Computing Use Statement and name of the CSP or PCS. Citations of publications resulting from the use of controlled-access datasets obtained through this DAR may also be posted on the dbGaP website.

  • Posting licensed content on any Website The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at xxxx://xxx.xxxxxxxxxxxxx.xxx/science/journal/xxxxx or the Elsevier homepage for books at xxxx://xxx.xxxxxxxx.xxx; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at xxxx://xxx.xxxxxxxx.xxx . All content posted to the web site must maintain the copyright information line on the bottom of each image. Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

  • Content You Provide You hereby grant to the Financial Institution and its service providers, including Central 1 and Yodlee Inc. (collectively, “Service Providers”) a license to use any information, data, passwords, materials or other content (collectively, “Your Content”) that you provide through or to the PFM Service for the following purposes:

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes.

Time is Money Join Law Insider Premium to draft better contracts faster.